Since bone metastasis is one of the most significant pathways in prostate cancer, we hypothesize that TLR‐9 may promote the bone metastasis of prostate cancer via stimulating MDSCs, and it depends on further studies to verify. Here, TLR9 is linked to prostate carcinoma.